| A21 | Defining CTL immunotherapy candidates against replication-competent and defective HIV | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
| A36 | Immunogens based on VLPs presenting epitopes of the HIV-1 fusion peptide | On-demand oral abstract session | Novel vectors and strategies |
| A6 | Plasma IL-21 associates with HIV-1 Neutralising potency of polyclonal IgG in the periphery | On-demand oral abstract session | Humoral immunity (including broadly neutralizing antibodies) |
| A9 | Novel multiplex analyses reveal disparate natural killer cell signaling pathway activation during lentivirus infection | On-demand oral abstract session | Systemic immune activation and inflammation |
| A17 | HIV modifies the m6A and m5C epitranscriptomic landscape of the host cell | On-demand oral abstract session | Host cellular factors and latency |
| A20 | GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture | On-demand oral abstract session | Eliminating and silencing latency |
| A5 | Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' between innate and adaptive immune cells in HIV controllers on ART | On-demand oral abstract session | Innate immunity |
| A9 | The circadian clock machinery regulates HIV transcription in CD4+ T cells | On-demand oral abstract session | Systemic immune activation and inflammation |
| A23 | RNA-directed gene therapy protects CD4+ T cells during HIV challenge and delays virus rebound post-ART in humanized mice | On-demand oral abstract session | Gene therapy |
| A21 | The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaques | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |